CompletedPhase 2NCT01521585

A Phase II Safety and Tolerability Study With SEN0014196

Studying Huntington's Disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Siena Biotech S.p.A.
Principal Investigator
Ralf Reilmann, MD
Dept. of Neurology, University of Münster - Germany
Intervention
SEN0014196(drug)
Enrollment
144 enrolled
Eligibility
30-70 years · All sexes
Timeline
20112012

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01521585 on ClinicalTrials.gov

Other trials for Huntington's Disease

Additional recruiting or active studies for the same condition.

See all trials for Huntington's Disease

← Back to all trials